BeiGene, Ltd. (NASDAQ:BGNE) has been the object of insider buying and selling activity recently. Director Donald W. Glazer let go of 47,149 shares at a price of $29.61 on September 27th. Glazer now owns $1,227,719 of stock per an SEC filing yesterday. Bros. Advisors Lp Baker, Director reported the purchase of 1,912,680 shares of (BGNE). The shares were purchased at an average price of $24.00. The Director now owns $41,359,344 of the stock according to the SEC filing.
Howard Liang, CFO & Chief Strategy Officer disclosed the purchase of 65,000 shares. The shares were bought on February 8th for an average price of $1.85. Liang now owns $120,250 of the stock per the Form 4 SEC filing.
Here are a few other firms who have also updated their positions. Price T Rowe Associates Inc /md/ expanded its holdings by buying 1,700 shares an increase of 0.4% from 03/31/2016 to 06/30/2016. Price T Rowe Associates Inc /md/ now controls 454,400 shares worth $13,541,000. The value of the position overall is up by 2.0%. As of the end of the quarter Ecor1 Capital, LLC had bought 159,614 shares growing its holdings by 1,012.4%. The value in dollars went from $462,000 to $5,226,000 a change of $4,764,000 quarter to quarter.
Goldman Sachs Group Inc trimmed its stake by selling 20,458 shares a decrease of 74.3%. Goldman Sachs Group Inc now holds 7,071 shares valued at $211,000. The total value of its holdings decreased 73.9%. As of quarter end Bank Of America Corp /de/ had acquired a total of 198 shares growing its position 618.8%. The value of the investment in BGNE increased from $1,000 to $7,000 a change of 600.0% since the last quarter.
Maxim Group started coverage with a rating of “Buy”. On February 29 analysts at Morgan Stanley released its first research report on the stock setting a rating of “Overweight”.
On February 29, 2016 Cowen & Company began coverage of the stock by announcing an initial rating of “Outperform”. Equity analyst Baird issued its first research report on the stock with an initial rating of “Outperform” and setting a price target of $44.00.
On February 29, 2016 Goldman Sachs started covering the stock giving it an initial rating of “Buy” and establishing a price target of $33.00.
The company is up since yesterday’s close of $29.49. Shares are trading at $30.23 which is slightly above the 50 day moving average which is $29.73 and a bit higher than the 200 day moving average of $29.03. The 50 day moving average went up $0.50 or +1.69% and the 200 day average went up by +4.12%.
In the last earnings report the EPS was $-4.80 and is projected to be $-3.38 for the current year with 32,903,000 shares now outstanding. Next quarter’s EPS is expected be $-0.88 with next year’s EPS projected to be $-3.28.
Traders are a little more bearish on BeiGene, Ltd. of late as implied by the uptick in short interest. The firm saw a rise in short interest of 0.01% between August 31, 2016 and September 15, 2016. Short interest grew 4,636 over that timeframe. With short interest at 774,604 and short average daily volume at 53,704, days to cover is 0.0 and the short interest percentage is 0.02% as of September 15.